X4 PharmaceuticalsXFOR
About: X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
Employees: 143
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
310% more call options, than puts
Call options by funds: $550K | Put options by funds: $134K
9% more capital invested
Capital invested by funds: $67.4M [Q3] → $73.2M (+$5.85M) [Q4]
10% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 21
1.23% less ownership
Funds ownership: 59.74% [Q3] → 58.51% (-1.23%) [Q4]
9% less funds holding
Funds holding: 98 [Q3] → 89 (-9) [Q4]
33% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 21
100% less funds holding in top 10
Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Swayampakula Ramakanth 25% 1-year accuracy 50 / 198 met price target | 393%upside $1.50 | Buy Reiterated | 7 Feb 2025 |
Financial journalist opinion









